| Followers | 19 |
| Posts | 6641 |
| Boards Moderated | 1 |
| Alias Born | 05/23/2019 |
Thursday, February 19, 2026 5:47:55 PM
WQLF SAYS: HAVE MERCY WQLF ahoooooo
Ai Generated
CV Sciences (CVSI) stock has shown positive momentum due to improved financial efficiency, including high gross margins ( in Q3 2025) and a strategic focus on cost reduction, aiming for profitability in 2026. Key drivers include the acquisition of Elevated Soft Gels for manufacturing, strong performance of new products (39% of Q3 2025 revenue), and a leading position in the natural product retail channel.
Key Reasons for CVSI Stock Movement:
Improved Profitability & Margins: The company has reported strong gross margins (approx.
- in 2025), driven by cost-saving initiatives and the acquisition of Elevated Soft Gels, which helps with insourcing production.
Strategic Growth & Innovation: New product launches, particularly in the non-cannabinoid space under the Plus Health brand, are contributing significantly to revenue, with products launched since 2023 representing 39% of Q3 2025 sales
Market Position: CVSI maintains a top position in the natural product retail channel.
Cost Management: The company is focusing on reducing operating expenses to reach positive cash flow, aiming for 2026 as a pivotal year for profitability.
Short-Term Momentum: Technical indicators as of early 2026 suggest a potential, albeit volatile, upward trend with support from moving averages.
Risks to Consider
Regulatory Uncertainty: The CBD market faces challenging federal regulations, which can impact sales.
Shrinking Revenue: Despite better margins, the company has faced year-over-year revenue declines in 2025 due to market competition and supply issues.
Volatile Performance: The stock has experienced significant, sometimes erratic, price swings.
Wolfman Jack Said ; What's Up ? CVSI YQU Understand
Have Mercy on Me ahoooooo
Ai Generated
CV Sciences (CVSI) stock has shown positive momentum due to improved financial efficiency, including high gross margins ( in Q3 2025) and a strategic focus on cost reduction, aiming for profitability in 2026. Key drivers include the acquisition of Elevated Soft Gels for manufacturing, strong performance of new products (39% of Q3 2025 revenue), and a leading position in the natural product retail channel.
Key Reasons for CVSI Stock Movement:
Improved Profitability & Margins: The company has reported strong gross margins (approx.
- in 2025), driven by cost-saving initiatives and the acquisition of Elevated Soft Gels, which helps with insourcing production.
Strategic Growth & Innovation: New product launches, particularly in the non-cannabinoid space under the Plus Health brand, are contributing significantly to revenue, with products launched since 2023 representing 39% of Q3 2025 sales
Market Position: CVSI maintains a top position in the natural product retail channel.
Cost Management: The company is focusing on reducing operating expenses to reach positive cash flow, aiming for 2026 as a pivotal year for profitability.
Short-Term Momentum: Technical indicators as of early 2026 suggest a potential, albeit volatile, upward trend with support from moving averages.
Risks to Consider
Regulatory Uncertainty: The CBD market faces challenging federal regulations, which can impact sales.
Shrinking Revenue: Despite better margins, the company has faced year-over-year revenue declines in 2025 due to market competition and supply issues.
Volatile Performance: The stock has experienced significant, sometimes erratic, price swings.
Wolfman Jack Said ; What's Up ? CVSI YQU Understand
Have Mercy on Me ahoooooo
Recent CVSI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:10:09 PM
- CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results • ACCESS Newswire • 05/14/2026 08:00:00 PM
- CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026 • ACCESS Newswire • 05/12/2026 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 08:04:10 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 09:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:06:03 PM
- CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results • ACCESS Newswire • 03/26/2026 08:00:00 PM
- CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026 • ACCESS Newswire • 03/24/2026 09:00:00 PM
- CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth • ACCESS Newswire • 03/10/2026 09:00:00 PM
- CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness • ACCESS Newswire • 02/26/2026 01:30:00 PM
- CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD • ACCESS Newswire • 12/23/2025 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:19:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:04:08 PM
- CV Sciences, Inc. Reports Third Quarter 2025 Financial Results • ACCESS Newswire • 11/13/2025 09:00:00 PM
- CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025 • ACCESS Newswire • 11/10/2025 11:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:24:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 09:23:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2025 08:01:09 PM
